These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28606761)

  • 1. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
    Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
    Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
    Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Advanced Tool To Interrogate BRD9.
    Karim RM; Schönbrunn E
    J Med Chem; 2016 May; 59(10):4459-61. PubMed ID: 27120693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
    Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
    J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
    Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
    Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
    J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
    Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
    Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
    Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
    J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
    Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
    Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
    Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
    Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.
    Klein DC; Lardo SM; Hainer SJ
    Cancer Res Commun; 2024 Jan; 4(1):237-252. PubMed ID: 38126767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
    Remillard D; Buckley DL; Paulk J; Brien GL; Sonnett M; Seo HS; Dastjerdi S; Wühr M; Dhe-Paganon S; Armstrong SA; Bradner JE
    Angew Chem Int Ed Engl; 2017 May; 56(21):5738-5743. PubMed ID: 28418626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
    Krämer KF; Moreno N; Frühwald MC; Kerl K
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations.
    Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
    Chem Biol Drug Des; 2019 Feb; 93(2):163-176. PubMed ID: 30225973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
    Clegg MA; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Leveridge M; Lindon M; Liwicki GM; Michon AM; Molnar J; Rioja I; Soden PE; Theodoulou NH; Werner T; Tomkinson NCO; Prinjha RK; Humphreys PG
    J Med Chem; 2020 Jun; 63(11):5816-5840. PubMed ID: 32410449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
    Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
    Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells.
    Kapoor S; Damiani E; Wang S; Dharmanand R; Tripathi C; Tovar Perez JE; Dashwood WM; Rajendran P; Dashwood RH
    Nutrients; 2022 Oct; 14(20):. PubMed ID: 36297001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.